HER1-based vaccine: Simultaneous activation of humoral and cellular immune response

The human epidermal growth factor receptor 1 (HER1) is a tumor-associated antigen that has been validated as a clinical target for several passive, non-immune therapies currently approved for the treatment of epithelial tumors. HER1 is an oncogene that not only promotes tumor progression and surviva...

Full description

Saved in:
Bibliographic Details
Published inSeminars in oncology Vol. 45; no. 1-2; pp. 75 - 83
Main Authors Bergado Báez, Gretchen, Hernández Fernández, Diana R., Mazorra Herrera, Zaima, Sánchez Ramírez, Belinda
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.01.2018
Subjects
cancer vaccine
HER1
immune response
cancer vaccine
immune response
HER1
Online AccessGet full text

Cover

More Information
Summary:The human epidermal growth factor receptor 1 (HER1) is a tumor-associated antigen that has been validated as a clinical target for several passive, non-immune therapies currently approved for the treatment of epithelial tumors. HER1 is an oncogene that not only promotes tumor progression and survival, but also immune escape. Its overexpression in some epithelial malignancies has been correlated with a poor prognosis. We developed an approach to target HER1 by specific active immunotherapy, recognizing the extracellular domain of the receptor, using a combination of VSSP and Montanide ISA 51 as adjuvants. We summarize the results obtained with this vaccine in both the preclinical and clinical settings, emphasizing the importance of the induction of both humoral and cellular responses for the success of cancer vaccines as safe therapeutic alternatives for the treatment of cancer.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0093-7754
1532-8708
DOI:10.1053/j.seminoncol.2018.05.002